AnaptysBio, Inc. ANAB
Updated: 17 Jun 2026
No signal published yet
We already track AnaptysBio and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow AnaptysBio, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow AnaptysBio free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 11, 2026, AnaptysBio reported its first-quarter financial results and announced the completion of the spin-off of its biopharma operations into First Tracks Biotherapeutics. The company transitioned to a royalty-focused business model, exclusively managing collaborations for Jemperli with GSK and imsidolimab with Vanda Pharmaceuticals. This restructuring aims to separate the company's development pipeline from its stable royalty assets.
What Firelda Watch includes for AnaptysBio, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow AnaptysBio, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow AnaptysBio free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more